IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentation
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany.
ANKET® is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. Innate’s latest innovation, the tetra-specific ANKET®, is the first NK cell engager technology to engage activating receptors (NKp46 and CD16), a tumor antigen and the interleukin-2 receptor (via an non-alpha IL-2 variant, IL-2v) via a single molecule. By providing proliferation and activation signals targeted to NK cells, tetra-specific ANKET® leverages the advantages of harnessing NK cell effector functions against cancer cells.
IPH6501, the first tetra-specific ANKET®, continues toward a Phase 1 clinical trial in 2023.
- Presentation: S258
- Title: IPH6501 is a first-in-class tetraspecific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas
- Session: s425 Gene therapy and immunotherapy - Biology & translational research
- Date and time: 10/06/2023, 11:30 - 12:45
- Location: Fantasie
- Speaker: Olivier Demaria, PhD, R&D Director, Science Leader at Innate Pharma